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ADEPT represents a potentially valuable means of effectively
destroying tumours without causing systemic toxicities (Sherwood,
1996; Bagshawe et al, 1998). The key element in this strategy is
tumour specificity; tumours are selectively targeted through the
antigens they express. ADEPT is a 2-step process which ultimately
leads to the production of high concentrations of active drug selec-
tively at the tumour site. The first step involves the administration
of an antibody-enzyme conjugate which is allowed to localize at
the tumour site and clear from normal tissue. A relatively nontoxic
prodrug is then administered and is converted by the enzyme to 
a cytotoxic drug by prelocalized enzyme. Both bacterial and
mammalian enzymes have been evaluated as potential candidates
for ADEPT, but so far, the bacterial enzyme carboxypeptidase has
been utilized in ADEPT clinical development due to its superior
activity in vitro and in animal studies. The enzyme has no known
mammalian equivalent and catalyses the hydrolytic cleavage of
glutamyl residues. Earlier work has previously demonstrated 
that a conjugate of CPG2 linked to the anti-CEA antibody, A5B7 
in combination with benzoic acid mustard glutamate prodrugs
resulted in significant antitumour activity (Blakey et al, 1993).
Responses were reported following a pilot clinical study of patients
with colorectal cancer using CPG2-F(ab¢)2 A5B7 conjugate to
activate the benzoic acid mustard prodrug prodrug 4-[2-
chloroethyl-(2mesyloxyethyl)amino] benzoyl-L-glutamic acid
(CMDA) (Napier et al, 2000). 
Animal models and previous clinical studies have demons-
trated that ADEPT can be used to selectively deliver an antibody-
enzyme conjugate to a tumour and produce significant regression
(Springer et al, 1991a; Eccles et al, 1994). These effects have not,
however, been correlated directly with production of the prodrug.
The ADEPT clinical trial sponsored by the CRC and AstraZeneca
commenced at the Royal Free Hospital in November 1997. The
formulation includes the bisiodophenol mustard ZD2767 which has
replaced the previously used CMDA. ZD2767 has the advantages
of increased potency and decreased half-life (Springer et al, 1995). 
The active drug produced from ZD2767P is a nitrogen mustard.
Nitrogen mustards have been extensively studied as chemothera-
peutic agents. Their primary mode of action is through alkylation
of DNA and, in particular, the production of DNA interstrand
crosslinks (ISC). The level of ISC has been shown to correlate
with cytotoxicity in in vitro studies (Sunters et al, 1992). Although
the quantitation of DNA ISC is relatively easy in vitro with tech-
niques such as alkaline filter elution, these methods are generally
not applicable to clinical studies. The single cell gel elec-
trophoresis (comet) assay has become established as a sensitive
method to analyse DNA strand breakage in vitro and in vivo
(Fairbairn et al, 1995). Recently we have optimized a modification
of this method to allow the detection of ISC following drug expo-
sure (Hartley et al, 1999). Cells are irradiated immediately prior to
analysis to deliver a fixed level of random strand breakage and
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compared to unirradiated controls. The method is more sensitive
than alkaline elution and can be used to assess clinical samples. It
also allows evaluation of heterogeneity in clinical specimens. For
example the formation and repair of ISC has been studied in the
lymphocytes of patients treated with ifosfamide (Hartley et al, 1999). 
Nitrogen mustards are good candidates for use in ADEPT since
they kill both quiescent and proliferating cells. Despite their suit-
ability for ADEPT, nitrogen mustards prodrugs, when activated,
tend to have a long chemical half life which results in non-tumour
tissue toxicity (Springer et al, 1991b). The bisiodophenol mustard
ZD2767 represents an improved prodrug component of ADEPT
compared to the original benzoic acid mustard CMDA and the 
4-[N,N-bis(2-chloroethyl)amino]-phenol prodrugs. When cleaved
by CPG2, ZD2767P produces a highly reactive nitrogen mustard
which has a short half life of 2 minutes in plasma (Blakey et al,
1996). Combination of CPG2-anti-CEA congugate and ZD2767P
has been reported to result in improved antitumour activity in a
colorectal tumour xenograft model and is currently in phase I
clinical trial. 
In the current study we sought to determine the major DNA
lesions produced by the ZD2767P ADEPT system and to establish
the kinetics of DNA damage and repair following treatment with
this compound. In so doing, the present study has highlighted the
value of the comet assay for measuring DNA lesions in vivo in
both animal model systems and in clinical samples. 
MATERIALS AND METHODS 
Materials 
All standard laboratory chemicals used in this study were commer-
cial products of AnalaR® grade purchased from Sigma (Poole,
UK). ZD2767P bisiodophenol was synthesized as previously
published (Springer et al, 1991a). The F(ab¢)2 fragment of A5B7
was conjugated to the bacterial enzyme CPG2 as described previ-
ously (Melton et al, 1993). 
CPG2 was produced as previously described (Sherwood et al,
1985) and kindly provided by Dr Roger Melton from the Division
of Biotechnology, CAMR, Porton Down, UK. 
Cell culture 
The human colorectal tumour cell line LS147T was maintained in
DMEM culture medium and 10% FCS supplemented with 2 mM
glutamine, at 37˚C in air containing 5% CO2. The cells were
routinely subcultured once a week. 
Growth inhibition studies 
The sulphorhodamine B (SRB) assay (Skehan et al, 1990) was
used to determine growth inhibition. The cells were seeded at 1 to
2 ´ 103 cells per well in a 96-well plate and left to adhere overnight
prior to drug exposure. Drug exposure was for 1 h, after which
time the cells were incubated at 37˚C for a further 4 days and then
fixed with 50 ml trichloroacetic acid for 20 minutes. The cells were
washed 5 times with tap water before incubation with 0.4% SRB
solution in 1% acetic acid. After washing 5 times in 1% acetic
acid, the plates were air dried overnight. The SRB stained cells
were then dissolved in 100 ml 10 mM Tris and the plates read at
540 nm using a plate reader. 
Measurement of interstrand crosslinks using the comet
assay 
The comet assay was performed under alkaline conditions as
described with modifications (Spanswick et al, 1998). Briefly, 
2.4 ´ 104 cells were embedded in 1% agarose on a microscope
slide then lysed in high salt buffer containing 2.5 M NaCl, 100 mm
disodium EDTA, 10 mM Tris-HCl (pH 10.5), 1% triton X-100.
After washing with H2O for 1 h, the cells were exposed to alkaline
buffer containing 50 mM NaOH, 1 mM disodium EDTA (pH 12.5)
for 40 min before electrophoresis at 18 V (20 min). The DNA was
then stained with propidium iodide and visualized using a fluores-
cent microscope. The Komet image analysis system was used to
measure the olive tail moment as percentage of DNA in the tail
multiplied by the comet length. For ISC measurements, samples
were first given a known dose of irradiation (10 Gy) before comet
analysis. The presence of ISC was seen as the reduction in tail
moment of the irradiated treated samples compared to the irradi-
ated untreated control samples. ISC were therefore quantified as
the percentage reduction in tail moment. Experiments in the
absence and presence of proteinase K have shown that he comet
assay as described measures interstrand crosslinks. 
In vivo studies 
The human colon adenocarcinoma cell line LS174T was used to
develop a xenograft model in the flank of female nude mice.
Subsequent passaging was by subcutaneous implantation of small
tumour pieces (~1 mm3). The tumour is a moderately differenti-
ated CEA-producing adenocarcinoma with small glandular acini
which secretes no measurable CEA into the circulation. All mice
were aged 2–3 months and weighed 20–23g at initiation of the
experiments. The experiments commenced when the tumours
were between 0.5–0.75 cm3 at approximately 2 weeks after
passaging. The F(ab¢)2 fragment of A5B7 was conjugated to the
bacterial enzyme CPG2 as previously described (Melton et al,
1993). 1 Unit of activity is defined as the amount of enzyme
required to catalyse the hydrolysis of 1 mmol min–1 ml–1 metho-
trexate in reaction mixture (Sherwood et al, 1985). Conjugate 
(25 U/mouse) was injected intravenously into the tail vein. CPG2
levels were monitored indirectly by a spectrophotometric assay
(Sherwood et al, 1985) and once a level of 0.1 U ml–1 had been
reached (72 h later) 75 mg kg–1 or 45 mg kg–1 ZD2767P was
administered intraperitoneally. Groups of 4 mice were killed 1 and
24 h later and the tumours were collected on ice. Using scalpel
blades, the tumours were finely chopped at 4˚C and made into 
a single cell suspension by gentle syringing using a 22-gauge
needle. Comet assays were then performed as detailed above. 
Clinical studies 
Informed consent both for the trial and for the biopsy procedure
was obtained. The protocol was approved by the Cancer Research
Campaign Central Institutional Review Board and the Royal Free
Hospital Local Ethics Committee (Phase I Trial of Antibody-
Directed Enzyme Prodrug Therapy (ADEPT) in Patients with
Advanced Colorectal Carcinoma and other CEA-Producing
Tumours CRC94/12 Protocol PH1/056). In patients for whom
consent was obtained for a tumour biopsy, samples were obtained
1 hour after the last prodrug injection. 10 ml blood for lymphocyte
studies was taken at the same time. Liver biopsies were obtained
by ultrasound guidance using TruCut technique under local
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centrifuging 8 ml of blood in vacutainer CPT™ tubes at 3000 rpm
for 20 min. The lymphocytes were washed twice using phosphate
buffered saline before analysis. Tumour samples were processed
into single cell suspensions as detailed above (in vivo section) 
and analysed using the comet assay. Localization of the conjugate
was achieved by detecting the presence of I131 iodine which was
attached to the F(ab¢)2 A5B7 antibody fragment. 
RESULTS 
Growth inhibition and interstrand crosslink production
by ZD2767P+/– CPG2 in vitro 
The growth inhibitory effect of a 1 h exposure to ZD2767P+/–
CPG2 was established for the LS147T human colorectal cell line
using the SRB assay (Figure 1a). The concentration of ZD2767P
alone resulting in 50% growth inhibition (IC50) was 55 ± 9 mM. In
contrast, co-incubation of ZD2767P with CPG2 resulted in an IC50
of 0.24 ± 0.11 mM. Therefore, ZD2767P was clearly activated by
the hydrolytic activity of CPG2. 
The critical DNA lesions produced by nitrogen mustards, ISC, can
be assessed by a modification of the comet assay as previously
described (Hartley et al, 1999). Preliminary investigations with
ZD2767 established that the formation of ISC occurs rapidly in cells
reaching a peak within 1 hour (data not shown). As seen in Figure 1b,
increasing the dose of ZD2767P (+CPG2) resulted in a corre-
sponding increase in ISC following a 1 h exposure to drug. Doses of
ZD2767P which resulted in growth inhibition (>10 mM) were also
associated with ISC formation. An equitoxic dose of ZD2767P alone
and ZD2767P + CPG2 (100 and 0.5 mM respectively) gave a similar
level of ISC. There was no detectable DNA strand breakage as
assessed by the comet assay at any dose tested (data not shown). 
The repair of ISC formed after a 1 hour exposure to 1 mM
ZD2767P + CPG2 was measured (Figure 2). In LS147T cells, ISC
were repaired rapidly with almost complete removal by 24 hours. 
ISC measurement in LS147T tumour xenografts 
Previous work has demonstrated that administration of 75 mg kg–1 of
ZD2767P 72 h after the conjugate A5B7 + CPG2 resulted in a signif-
icant antitumour response in an LS174T xenograft model (18). 
To determine if the modified comet assay could be used to assess
DNA damage in vivo, mice with implanted xenografts of LS174T
cells were treated with ZD2767P following administration of the
conjugate. The antibody/enzyme conjugate was administered at 
25 U/mouse 72 hours prior to injection of prodrug. Two doses of pro-
drug were used in different groups of mice: therapeutic (75 mg kg–1)
and subtherapeutic (45 mg kg–1) (Blakey et al, 1996). Following
sacrifice of mice, biopsies were analysed at 1 and 24 hours follow-
ing administration of ZD2767P. The results of experiments, using 
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Figure 1 (A) In vitro growth inhibition of ZD2767P and ZD2767P + CPG2 in LS174T colorectal tumour cells. Growth inhibition was assessed in LS174T cells
following a 1 h exposure to ZD2767P (n) or ZD2767P + CPG2 (n n) using the SRB assay after 4 days in drug free medium. Symbols represent the mean of 4
separate determinations. (B) ISCL formation in LS174T colorectal tumour cells following ZD2767P. The cells were treated with 0.5, 1, 10 or 100 mM ZD2767P
with or without CPG2 for 1 h before cells were harvested and analysed using the comet assay. Columns represent the mean ± SD from 3 separate experiments 
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Figure 2 Formation and repair of ISCL in LS174T colorectal cell line
following ZD2767P + CPG2. Cells were treated with 1 mM ZD2767P + CPG2
for 1 h before resuspension in drug-free medium for up to 96 h. At various
time points after the initial drug exposure, the cells were harvested and
analysed for the presence of ISCL using the comet assay 4 animals for each time point and drug concentration, are indicated in
Figure 3. Administration of prodrug (75 mg kg–1) for 1 h, 72 h after
administration of the antibody/enzyme conjugate, resulted in signifi-
cant production of ISC (Figure 3A). Biopsies obtained from animals
24 hours after the prodrug administration demonstrated that a signif-
icant number of ISC had been repaired as reflected in the < 25%
reduction in tail moment (Figure 3B). At 1 hour following adminis-
tration of 45 mg kg–1 there was greatly reduced formation of ISC
compared to 75 mg kg–1 (Figure 3C). Assays performed on biopsies
of tumours from untreated animals showed no evidence of ISC (data
not shown). These experiments confirm that the comet assay can be
used to measure ISC in vivo, that administration of therapeutic doses
is associated with formation of crosslinks, and that the level of
detectable lesions is related to the dose of drug administered. 
Analysis of clinical specimens obtained during a
clinical study of ADEPT 
Having established that the administered dose of ZD2767 signifi-
cantly correlates with the extent of ISC in vitro and in vivo, we
investigated whether there were detectable lesions in patients
treated with ADEPT. Samples were obtained during the clinical
trial carried out in the Royal Free Hospital; the full results of this
Phase I study will be published subsequently. Samples from
patients were obtained 1 hour following intravenous injection of
ZD2767P. In view of the difficulty of obtaining biopsies within
such a limited time from treatment, only 5 specimens could 
be obtained. These patient samples were analysed as shown in
Table 1 with results shown as reduction in tail moment compared
with control samples of hepatic metastases from untreated
colorectal cancer patients obtained at the time of resection. In
addition, bone marrow samples were taken from 2 patients where
tumour was not accessible for biopsies. Peripheral blood lympho-
cytes taken at the same time were also analysed. 
There were few detectable ISC in the lymphocytes obtained or
in the 2 bone marrow aspirates (data not shown). Tumour biopsy
samples also showed no evidence of ISC except in one case
(patient 3). In this patient a significant reduction in tail moment
was seen following irradiation of the sample. This patient’s
lymphocytes also showed a lesser (24%) reduction in tail moment
indicating some peripheral activation of prodrug. Data from
patients 3 and 4 are shown in Figure 4. Following irradiation of
biopsies and lymphocytes from the treated patient and an untreated
control, a similar increase in tail moment was detected indicating
an absence of ISC. In contrast the biopsy from patient 3 showed 
no alteration in tail moment indicating the presence of ISC. It is 
of interest that this is the only case of those sampled in which
good localization of antibody-enzyme conjugate was observed by
phosphorimage analysis and spectrophotometric assay (data not
shown). Furthermore this patient demonstrated a response to
therapy as shown by decrease in serum CA19–9 levels and stabi-
lization of previously progressive liver metastasis. 
DISCUSSION 
The development of novel therapies targeting tumours has
extended the scope of phase I clinical trials in assessing feasibility
in terms of maximal toxicity. It is increasingly important to
directly analyse tumour material to determine if proposed mech-
anisms of action are operative. The investigation of material
obtained following treatment with DNA-damaging agents has
been revolutionized by the use of the comet assay. This allows
quantitative estimation of DNA damage and repair on small
amounts of clinical material following drug exposure, and has
been extensively validated. Recent work from our department on
lymphocytes from patients receiving ifosfamide therapy demon-
strated that modification of this technique allowed measurement 
of interstrand crosslinks, which are the critical cytotoxic lesions
produced by nitrogen mustards. ADEPT has the potential to
greatly enhance antitumour selectivity of cancer therapy by acti-
vating high concentrations of chemotherapeutic agents selectively
at tumour sites. The rationale for ADEPT, previous in vitro studies
and clinical experience have been well described (Springer and
Niculescu-Duvaz, 1997). In this trial the active chemotherapeutic
1674 SD Webley et al 
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Figure 3 ZD2767P + CPG2 ISCL formation in vivo. 3 groups of 4 animals were either treated with: (A) 75 mg kg–1 for 1 h; (B) 75 mg kg–1 for 24 h or 
(C) 45 mg kg–1 for 1 h before tumours were excised and analysed for DNA damage using the comet assay. Untreated animal tumours showed no DNA damage 
Patient No.
1
2
3
4
5
Biopsy
0
0
80
8
17
Lymphocytesa
% reduction in tail moment
0
0
24
8
6
Liver
Site of
metastasis
Liver
Liver
Liver
Liver
Table 1 Patient clinical data 
aFrom whole blood lymphocytesagent is ZD2767, a bisiodophenol mustard with a short half life
and high potency which are optimal characteristics for preventing
systemic toxicity in a tumour-targeting system. The critical intra-
cellular lesion resulting in cytotoxicity following treatment with
bifunctional nitrogen mustards has been demonstrated to be the
interstrand crosslink (Sunters et al, 1992). The purpose of this
study was to determine the kinetics of crosslink formation and
repair in cell culture and xenograft models and to apply this
information to the analysis of clinical samples. 
Our initial experiments demonstrate that the peak formation of
crosslinks occurred within 2 hours. There was a good correlation
seen between the extent of crosslinks and cytotoxicity. Repair of
lesions was complete by 24 h. There were no detectable single or
double DNA strand breaks. The ZD2767P prodrug was active only
at >10 mM concentration; at the doses required for cytotoxicity,
interstrand crosslinks were detectable. Experiments using the
LS174T xenograft model confirmed the ability of the modified
comet assay to detect DNA lesions from in vivo studies which had
similar time course to cell lines and a similar relationship between
dose and crosslink formation. 
There are several difficulties in applying these assays to the clin-
ical setting. Apart from the inherent logistical problems in obtaining
samples for analysis, the material obtained may not be representative
of the tumour as a whole or may be heterogeneous itself. Furthermore
there is no possibility of obtaining material before treatment. Based
on data obtained from the preclinical studies, we performed biopsies
1 hour following administration of prodrug. However in this study
we were only able to obtain tumour samples from 5 patients on the
ADEPT study and used material from patients with untreated
metastatic cancer or in peripheral lymphocytes from patients who
received ADEPT. It is of interest that the one sample in which signif-
icant crosslinks could be detected was taken from the patient in
whom both good uptake of antibody conjugate and tumour marker
response were found. The reduction in tail moment in this sample
was in the range found in biopsies from animals given therapeutic
doses of ADEPT. This indicates that the degree of ISC in the
responding patient corresponded to that found in xenograft models. 
In summary this study validates the use of the comet assay in
assessing DNA damage in clinical samples with small amounts of
tissue. It has demonstrated the feasibility of characterizing and
quantitating DNA damage and repair in a variety of clinical
settings and will be critical for integrating target validation in
further clinical trials of cytotoxic agents. 
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